Method for predicting clinical outcome of patients with non-small cell lung carcinoma
The invention provides an in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient.
1. An in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient, wherein said genes are GRM8, NRF1, USP7, PRO0149, TXNL48, GLG1, ZNRF1, and UBE2L3, wherein the expression level of said at least 8 genes is determined by determining the number of gene copies of said genes and the number of gene copies of said genes is quantified by a microarray-based comparative genomic hybridization (CGH) method or by a DNA chip based method.
2. The method of claim 1 , wherein the patient is affected with an adenocarcinoma.
3. The method of claim 1 , wherein the patient is affected with squamous cell carcinoma.
4. The method of claim 1 , wherein the patient was diagnosed with a Stage I carcinoma.
5. The method of claim 4 , wherein the patient was diagnosed with a Stage IB carcinoma.
6. The method of claim 1 , further comprising the step of comparing the combined expression level of said genes with reference values.
7. The method of claim 1 , wherein overexpression of said genes is used to assign a prognosis to a patient or assign a patient to a chemotherapeutic treatment.
8. The method of claim 1 , wherein the biological sample is a tumor sample.
9. The method of claim 1 , further comprising determining the expression level of the genes listed in Table B, or of a subcombination thereof.
10. The method of claim 9 , comprising determining the expression level of any or all of the genes listed in Table C.
11. The method of claim 10 , comprising determining the expression level of any or all of the genes listed in Table D.
12. The method of claim 11 , comprising determining the expression level of any or all of the genes listed in Table E.